Ascendis Pharma A/S Purchase Of Treasury Shares
Ascendis Pharma A/S (ASND) reported Purchase Of Treasury Shares of EUR 17.40 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-02-11.
Financial Statements › Notes
ifrs-full:PurchaseOfTreasuryShares · last filed 2026-02-11
- Ascendis Pharma A/S purchase of treasury shares for the quarter ending 2025-12-31 was 0.00 EUR.
- Ascendis Pharma A/S purchase of treasury shares for the quarter ending 2025-09-30 was 0.00 EUR.
- Ascendis Pharma A/S purchase of treasury shares for the quarter ending 2025-06-30 was 0.00 EUR.
- Ascendis Pharma A/S purchase of treasury shares for the quarter ending 2025-03-31 was 17.40M EUR.
| Period end | Purchase Of Treasury Shares 3 month | Purchase Of Treasury Shares 6 month | Purchase Of Treasury Shares 9 month | Purchase Of Treasury Shares 12 month |
|---|---|---|---|---|
| 2025-12-31 | 0.00 EUR derived: 20-F 12 month − 6-K 9 month · filed 2026-02-11 | 0.00 EUR derived: sum of 2 quarters · filed 2026-02-11 | 0.00 EUR derived: sum of 3 quarters · filed 2026-02-11 | 17.40M EUR 20-F · filed 2026-02-11 |
| 2025-09-30 | 0.00 EUR derived: 6-K 9 month − 6-K 6 month · filed 2025-11-12 | 0.00 EUR derived: sum of 2 quarters · filed 2025-11-12 | 17.40M EUR 6-K · filed 2025-11-12 | |
| 2025-06-30 | 0.00 EUR derived: 6-K 6 month − 6-K 3 month · filed 2025-08-07 | 17.40M EUR 6-K · filed 2025-08-07 | ||
| 2025-03-31 | 17.40M EUR 6-K · filed 2025-05-01 | |||
| 2023-12-31 | 106.10M EUR 20-F · filed 2025-02-12 | |||
| 2022-12-31 | 0.00 EUR derived: 20-F 12 month − 6-K 9 month · filed 2024-02-07 | 0.00 EUR derived: sum of 2 quarters · filed 2024-02-07 | 0.00 EUR derived: sum of 3 quarters · filed 2024-02-07 | 106.10M EUR 20-F · filed 2024-02-07 |
| 2022-09-30 | 0.00 EUR derived: 6-K 9 month − 6-K 6 month · filed 2023-11-07 | 0.00 EUR derived: sum of 2 quarters · filed 2023-11-07 | 106.10M EUR 6-K · filed 2023-11-07 | |
| 2022-06-30 | 0.00 EUR derived: 6-K 6 month − 6-K 3 month · filed 2023-09-05 | 106.10M EUR 6-K · filed 2023-09-05 | ||
| 2022-03-31 | 106.10M EUR 6-K · filed 2023-04-27 | |||
| 2021-12-31 | 21.61M EUR 20-F · filed 2024-02-07 |